500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN, MA
Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
Kymera Therapeutics Elects Class III Directors at Annual Meeting
COO Jeremy Chadwick Resigns; Will Remain as Advisor Until November 2026
Announces First Quarter 2026 Financial Results and Provides a Business Update
Annual Report to Security Holders
News, Articles of Incorporation
Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Kymera Therapeutics Enters $500 Million Sales Agreement with TD Cowen
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence